Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2023-09-29 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice from Bafna Pharmaceuticals Limited addressed to stock exchanges regarding the closure of the "Trading Window" for insiders and connected persons. It references SEBI regulations on insider trading and specifies the period during which trading in the company's shares is prohibited due to the upcoming declaration of audited financial results for the quarter ending September 30, 2023. The document does not contain any financial data, results, or detailed report content but is an announcement related to trading restrictions ahead of financial results disclosure. It is a regulatory compliance announcement rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (2216 characters), and it is clearly an announcement, not the report itself.
2023-09-29 English
Resignation of Independent director
Regulatory Filings
2023-09-26 English
Shareholders meeting
Regulatory Filings
2023-09-25 English
Resignation
Regulatory Filings
2023-09-23 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is titled as "Proceedings of 28th Annual General Meeting (AGM)" and details the summary of the AGM held on September 22, 2023. It includes information about the meeting format (video conference), attendees (directors, auditors, members), agenda items discussed, resolutions passed, and voting procedures. The document does not contain full financial statements or detailed financial performance data but rather a summary of the meeting proceedings and resolutions. It also mentions that the detailed voting results and scrutinizer's report will be separately disclosed later. The document length is about 9805 characters, which is substantial but the content is clearly a meeting summary rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including summaries of proceedings.
2023-09-22 English
Offer for sale
Regulatory Filings
2023-09-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.